Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
ASP Isotopes Inc. Executive Chairman Paul Elliot Mann reported an open-market sale of 162,153 shares of common stock at a weighted average price of $5.436 per share. According to the disclosure, these were “sell to cover” transactions under a Rule 10b5-1 trading plan to satisfy tax withholding on the quarterly vesting of a restricted stock award.
After these sales, Mann held 7,597,385 shares of ASP Isotopes common stock directly. The filing notes the shares were sold in multiple transactions at prices ranging from $5.10 to $5.57 per share.
Independent Trading Group Inc. (ASPI) filed a Form 144 reporting a proposed sale of 1,441,361 shares of common stock, listed as acquired as compensation under a restricted stock award on 04/14/2025.
The filing identifies the securities as common stock to be sold through NASDAQ and cites the 04/14/2025 grant date; cash‑flow treatment and exact planned sale timing are not shown in the excerpt.
ASP Isotopes’ subsidiary Quantum Leap Energy has deepened its collaboration with the South African Nuclear Energy Corporation (Necsa) by signing a Pre-Implementation Services Contract for a planned High Assay Low Enriched Uranium (HALEU) enrichment facility at Necsa’s Pelindaba site.
Under the agreement, Necsa will provide facilities, infrastructure, utilities and services to support the siting, design, construction, commissioning and operation of the enrichment facility. A joint committee with representatives from both parties will oversee implementation, aiming to bring QLE’s HALEU production capabilities to market readiness.
The partnership combines QLE’s proprietary Aerodynamic Separation Process and Quantum Enrichment technologies with Necsa’s established nuclear infrastructure and global networks. It targets growing demand for HALEU, a key fuel for small modular and other advanced reactors, as advanced nuclear projects scale to serve data centers and industrial electrification.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy (QLE), has created a Strategic Advisory Board to support its plans in the nuclear fuel sector and appointed two initial members, nuclear engineering academic leader Mary Lou Dunzik-Gougar and advanced materials executive Kevin Kramer.
The board is expected to guide QLE as it develops proprietary technologies to address inefficiencies, environmental concerns, and supply chain vulnerabilities across the nuclear fuel cycle, including front-end enrichment activities and back-end waste treatment technologies for advanced reactors, fusion systems, and the existing nuclear fleet.
ASP Isotopes Inc. received an updated ownership report on its common stock from shareholder Paul E. Mann. Mann reported beneficial ownership of 7,759,538 shares of common stock, representing 7.0% of the class, as of 12/31/2025. He has sole voting and dispositive power over all reported shares, with no shared voting or investment power disclosed.
ASP Isotopes, through its wholly owned subsidiary Quantum Leap Energy (QLE), plans to establish QLE’s new global corporate headquarters in Austin, Texas. The move is intended to strengthen its Texas presence and position the development-stage nuclear fuels company closer to its U.S. customer base.
QLE also plans a significant operational presence in Texas, working with Fermi America under an existing memorandum of understanding to pursue a joint venture for a high-assay low-enriched uranium enrichment research and commercial production facility linked to Fermi America’s hypergrid campus in Amarillo. This would be developed alongside ASP Isotopes’ planned commercial facility for stable isotopes and advanced nuclear materials.
The announcement highlights Texas’ supportive regulatory and business environment for nuclear power and notes U.S. Department of Energy estimates that domestic demand for HALEU could reach 50 metric tons per year by 2035 and 500 metric tons per year by 2050, underscoring the potential market for advanced nuclear fuels.
BNP Paribas Asset Management UK Ltd has filed an amended Schedule 13G reporting beneficial ownership of 944,326 shares of ASP Isotopes Inc. common stock, representing 0.9% of the outstanding class as of December 31, 2025. The firm reports sole voting and dispositive power over all of these shares and confirms they are held in the ordinary course of business, not to change or influence control of ASP Isotopes.
ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock at an original purchase price of $2.2952 per share. The preferred stock is convertible into Opeongo common stock and carries anti-dilution protections, voting rights, and the ability for Series Seed-1 holders to elect a dedicated director while enough shares remain outstanding.
ASP Isotopes and other investors also received veto rights over certain major Opeongo corporate actions and contractual protections through investors’ rights, right of first refusal and co-sale, and voting agreements. Within thirty days after January 26, 2026, ASP Isotopes and Opeongo are obligated to negotiate a draft supply agreement giving ASP Isotopes a right of first offer for medical isotope supply tied to Opeongo’s future pharmaceutical products.
The Vanguard Group reported a passive ownership stake in ASP Isotopes Inc common stock on a Schedule 13G. Vanguard beneficially owns 6,406,244 shares, representing 5.77% of the outstanding common stock. It has shared voting power over 873,110 shares and shared dispositive power over all 6,406,244 shares, with no sole voting or dispositive authority.
Vanguard states the shares are held in the ordinary course of business, not to change or influence control of ASP Isotopes. Following an internal realignment on January 12, 2026, certain Vanguard subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies as before.
ASP Isotopes Inc. filed a current report to share that it issued a press release providing a production update on the Helium Project of Renergen Limited. The press release, dated January 29, 2026, is attached as Exhibit 99.1 and is incorporated by reference into the report.
The information is furnished under Regulation FD, meaning it is intended to ensure broad, non-selective disclosure. The company also notes that the press release contains forward-looking statements covered by the Private Securities Litigation Reform Act safe harbor provisions.